metformin and Cancer of Skin studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

Excerpt	Relevance	Reference
"Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive."	8.31	Association of metformin use and survival in patients with cutaneous melanoma and diabetes. ( Andersson, TML; Eriksson, H; Girnita, A; Häbel, H; Ingvar, C; Krakowski, I; Nielsen, K; Smedby, KE, 2023)
"The combined treatment of metformin with trametinib and paclitaxel showed divergent effects on melanoma cell viability."	8.02	Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells. ( Lee, Y; Park, D, 2021)
"In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet."	7.80	Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014)
"Malignant melanoma is a life-threatening form of skin cancer with a low response rate to single-agent chemotherapy."	5.62	Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. ( Chen, S; Liu, C; Song, M; Tao, Z; Xia, W; Zhang, W; Zhu, B, 2021)
"Melanoma is the most dangerous and treatment-resistant skin cancer."	5.46	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. ( Albini, A; Argenziano, G; Ciarrocchi, A; Dallaglio, K; Dominici, M; Grisendi, G; Longo, C; Petrachi, T; Romagnani, A, 2017)
"Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive."	4.31	Association of metformin use and survival in patients with cutaneous melanoma and diabetes. ( Andersson, TML; Eriksson, H; Girnita, A; Häbel, H; Ingvar, C; Krakowski, I; Nielsen, K; Smedby, KE, 2023)
"The combined treatment of metformin with trametinib and paclitaxel showed divergent effects on melanoma cell viability."	4.02	Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells. ( Lee, Y; Park, D, 2021)
"In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet."	3.80	Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014)
"Several reports have demonstrated the inhibitory effect of metformin, a widely used drug in the treatment of type 2 diabetes, on the proliferation of many cancers including melanoma."	3.80	Inhibition of melanogenesis by the antidiabetic metformin. ( Abbe, P; Ballotti, R; Bertolotto, C; Cerezo, M; Chignon-Sicard, B; Lehraiki, A; Passeron, T; Regazzetti, C; Rocchi, S; Rouaud, F, 2014)
"The Nitrosogenesis of skin cancer is a newly introduced concept in medical science, the significance of which is yet to be the subject of detailed analyses and discussions."	1.91	NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAR ( Tchernev, G, 2023)
"Metformin was administered before and during the induction of resistance to DTIC (MET-DTIC)."	1.72	Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance. ( Cecchini, AL; Cecchini, R; da Silva Brito, WA; Lopes, NMD; Luiz, RC; Marinello, PC; Sanches, LJ, 2022)
"Metformin was associated with a lower risk of developing BCC (OR, 0."	1.62	Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. ( Adalsteinsson, JA; Feng, H; Jonasson, JG; Kristjansson, AK; Muzumdar, S; Olafsdottir, GH; Ratner, D; Silverberg, JI; Tryggvadottir, L; Ungar, J; Waldman, R; Wu, R, 2021)
"0."	1.62	Possible treatment for UVB-induced skin injury: Anti-inflammatory and cytoprotective role of metformin in UVB-irradiated keratinocytes. ( Chen, X; Chen, Y; Gu, H; Li, M; Lin, S; Song, C; Xiao, T; Xu, S, 2021)
"Malignant melanoma is a life-threatening form of skin cancer with a low response rate to single-agent chemotherapy."	1.62	Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. ( Chen, S; Liu, C; Song, M; Tao, Z; Xia, W; Zhang, W; Zhu, B, 2021)
"To evaluate skin cancer risk associated with metformin use."	1.48	Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. ( Tseng, CH, 2018)
"Melanoma is the most dangerous and treatment-resistant skin cancer."	1.46	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. ( Albini, A; Argenziano, G; Ciarrocchi, A; Dallaglio, K; Dominici, M; Grisendi, G; Longo, C; Petrachi, T; Romagnani, A, 2017)
"Metformin is a biguanide widely prescribed as a first-line antidiabetic drug in type 2 diabetes mellitus patients."	1.42	Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma. ( Guo, X; Liu, B; Liu, GJ; Miao, G; Zhang, X, 2015)
"Melanoma is a largely incurable skin malignancy owing to the underlying molecular and metabolic heterogeneity confounded by the development of resistance."	1.42	Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. ( Bhat, MK; Chaube, B; Malvi, P; Meena, AS; Mohammad, N; Singh, SV, 2015)
"Treatment with melatonin and metformin and their combinations was followed by significantly lower tumor multiplicity and smaller size, longer latency period and survival of tumor-bearers."	1.36	[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice]. ( Anisimov, VN; Deriabina, ON; Plotnikova, NA, 2010)

Research

Studies (30)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Hazard Ratio for Surgically Treated KC

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (46.67)	24.3611
2020's	16 (53.33)	2.80

Authors	Studies
Sanches, LJ	1
Marinello, PC	2
da Silva Brito, WA	1
Lopes, NMD	1
Luiz, RC	1
Cecchini, R	2
Cecchini, AL	2
Remenár, É	1
Dóczi, R	1
Dirner, A	1
Sipos, A	1
Perjési, A	1
Tihanyi, D	1
Vodicska, B	1
Lakatos, D	1
Horváth, K	1
Kajáry, K	1
Schwáb, R	1
Déri, J	1
Lengyel, CG	1
Várkondi, E	1
Vályi-Nagy, I	1
Peták, I	1
Misitzis, A	3
Stratigos, A	1
Mastorakos, G	2
Weinstock, M	1
Krakowski, I	1
Häbel, H	1
Nielsen, K	1
Ingvar, C	1
Andersson, TML	1
Girnita, A	1
Smedby, KE	1
Eriksson, H	1
Tchernev, G	1
Ravishankar, A	1
Zhang, T	1
Lindgren, BR	1
Farah, RS	1
Dong, Z	1
Goldfarb, NI	1
Chang, MS	1
Hartman, RI	1
Xue, J	1
Giovannucci, EL	1
Nan, H	1
Yang, K	1
Stratigos, AJ	1
Beatson, M	1
Dellavalle, RP	2
Weinstock, MA	2
Souza-Neto, FP	1
Melo, GP	1
Ramalho, LZN	1
Cela, EM	1
Campo, VE	1
González-Maglio, DH	1
Adalsteinsson, JA	2
Muzumdar, S	1
Waldman, R	2
Wu, R	1
Ratner, D	2
Feng, H	2
Ungar, J	1
Silverberg, JI	1
Olafsdottir, GH	1
Kristjansson, AK	1
Tryggvadottir, L	2
Jonasson, JG	2
Xiao, T	1
Chen, Y	1
Song, C	1
Xu, S	1
Lin, S	1
Li, M	1
Chen, X	1
Gu, H	1
Song, M	1
Xia, W	1
Tao, Z	1
Zhu, B	1
Zhang, W	1
Liu, C	1
Chen, S	1
Lee, Y	1
Park, D	1
Xu, A	1
Lee, J	1
Zhao, Y	1
Wang, Y	1
Li, X	1
Xu, P	1
Tseng, CH	1
Cristofoletti, C	1
Bresin, A	1
Picozza, M	1
Picchio, MC	1
Monzo, F	1
Helmer Citterich, M	1
Passarelli, F	1
Frezzolini, A	1
Scala, E	1
Monopoli, A	1
Cantonetti, M	1
Benucci, R	1
D'Atri, S	1
Caprini, E	1
Russo, G	1
Narducci, MG	1
Yu, X	1
Zhou, W	1
Wang, H	1
Lu, S	1
Jin, Y	1
Fu, J	1
Checkley, LA	1
Rho, O	1
Angel, JM	1
Cho, J	1
Blando, J	1
Beltran, L	1
Hursting, SD	1
DiGiovanni, J	1
Reddi, A	1
Powers, MA	1
Lehraiki, A	1
Abbe, P	1
Cerezo, M	2
Rouaud, F	1
Regazzetti, C	1
Chignon-Sicard, B	1
Passeron, T	1
Bertolotto, C	1
Ballotti, R	2
Rocchi, S	2
Tomic, T	1
Miao, G	1
Liu, B	1
Guo, X	1
Zhang, X	1
Liu, GJ	1
Livingstone, E	1
Swann, S	1
Lilla, C	1
Schadendorf, D	1
Roesch, A	1
Verduzco, D	1
Flaherty, KT	1
Smalley, KS	1
Chaube, B	1
Malvi, P	1
Singh, SV	1
Mohammad, N	1
Meena, AS	1
Bhat, MK	1
Petrachi, T	1
Romagnani, A	1
Albini, A	1
Longo, C	1
Argenziano, G	1
Grisendi, G	1
Dominici, M	1
Ciarrocchi, A	1
Dallaglio, K	1
Deriabina, ON	1
Plotnikova, NA	2
Anisimov, VN	2
Man'cheva, TA	1
Demidov, DV	1
Kharitonova, TV	1
Pashkevich, IV	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912]	Phase 4	954 participants (Actual)	Interventional	2009-06-26	Completed
THE METFORMIN AND TRICHLOROACETIC ACID IN TREATMENT OF MELASMA[NCT03475524]	Phase 4	60 participants (Anticipated)	Interventional	2019-04-01	Recruiting
A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients[NCT01638676]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2012-07-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years

The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed

Intervention	participants (Number)
Arm 1: 5-fluorouracil	182
Arm 2: Placebo, Vehicle Control	177

Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years

Article	Year
Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies. Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:1 Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Observational Studies as Topic; Prediabetic State; Ran	2021
Is it time to test biguanide metformin in the treatment of melanoma? Pigment cell & melanoma research, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Humans; Melanoma; Metformin; Models, Biological; Signal Transduction; Skin Ne	2015

Article	Year
Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance. Cell biology international, 2022, Volume: 46, Issue:1 Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tu	2022
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With JCO precision oncology, 2022, Volume: 6 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Drug	2022
Association of metformin use and survival in patients with cutaneous melanoma and diabetes. The British journal of dermatology, 2023, 01-23, Volume: 188, Issue:1 Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Melanoma; Melanoma, C	2023
NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAR Georgian medical news, 2023, Issue:339 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-C	2023
The effect of metformin on the risk of recurrent nonmelanoma skin cancers. International journal of dermatology, 2020, Volume: 59, Issue:8 Topics: Carcinoma, Basal Cell; Humans; Metformin; Neoplasm Recurrence, Local; Skin Neoplasms	2020
The association of metformin use with keratinocyte carcinoma development in high-risk patients. Dermatologic therapy, 2020, Volume: 33, Issue:6 Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms	2020
Metformin inhibits the inflammatory and oxidative stress response induced by skin UVB-irradiation and provides 4-hydroxy-2-nonenal and nitrotyrosine formation and p53 protein activation. Journal of dermatological science, 2020, Volume: 100, Issue:2 Topics: Aldehydes; Animals; Carcinogenesis; DNA Damage; Female; Humans; Melanoma; Metformin; Mice; Oxidative	2020
Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:1 Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Case-Control Studies; Female; Hedgehog Proteins; Hum	2021
Possible treatment for UVB-induced skin injury: Anti-inflammatory and cytoprotective role of metformin in UVB-irradiated keratinocytes. Journal of dermatological science, 2021, Volume: 102, Issue:1 Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Carcinogenesis; Disease Models, Animal	2021
Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. Drug delivery, 2021, Volume: 28, Issue:1 Topics: Animals; Apoptosis; Cell Survival; Chemistry, Pharmaceutical; Cholesterol; Doxorubicin; Drug Carrier	2021
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells. Anticancer research, 2021, Volume: 41, Issue:3 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Syne	2021
Reply to: Metformin use and keratinocyte carcinoma risk. Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:4 Topics: Carcinoma, Basal Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms	2021
Metformin use and keratinocyte carcinoma risk. Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:4 Topics: Carcinoma, Basal Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms	2021
Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells. Journal of Zhejiang University. Science. B, 2021, Jul-15, Volume: 22, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Nucleus;	2021
Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:4 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle	2018
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia, 2019, Volume: 33, Issue:5 Topics: Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Copy Number Variations; Humans;	2019
Transdermal metformin hydrochloride-loaded cubic phases: in silico formulation optimization, preparation, properties, and application for local treatment of melanoma. Drug delivery, 2019, Volume: 26, Issue:1 Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Hypoglyce	2019
Metformin inhibits skin tumor promotion in overweight and obese mice. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:1 Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet;	2014
Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora. Experimental dermatology, 2014, Volume: 23, Issue:5 Topics: Chemoprevention; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mel	2014
Inhibition of melanogenesis by the antidiabetic metformin. The Journal of investigative dermatology, 2014, Volume: 134, Issue:10 Topics: Animals; Biopsy; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cyclic AMP; Dose-Response Re	2014
Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Femal	2015
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma. Experimental dermatology, 2015, Volume: 24, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug Resistance, Multiple; Drug Res	2015
Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. Experimental dermatology, 2015, Volume: 24, Issue:9 Topics: Adaptation, Physiological; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Hypoglycemic Ag	2015
Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Lin	2015
Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget, 2017, Jan-24, Volume: 8, Issue:4 Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation;	2017
[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice]. Voprosy onkologii, 2010, Volume: 56, Issue:5 Topics: Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma, Squamous Cell; Catalase; Central Nervous	2010
Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice. Bulletin of experimental biology and medicine, 2011, Volume: 151, Issue:3 Topics: Animals; Antioxidants; Benzo(a)pyrene; Cell Transformation, Neoplastic; Female; Lipid Peroxidation;	2011

metformin and Cancer of Skin